Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?

BJU International

Volumn 114, Issue 4, 2014, Pages 476-483

  Wolff, Johannes M ^a   Abrahamsson, Per Anders ^b   Irani, Jacques ^c   Calais Da Silva, Fernando ^d  

^a AKH Viersen ^*  (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d Universidade de Lisboa   (Portugal)

Author keywords

androgen deprivation; intermittent therapy; prostate cancer; prostate specific antigen; quality of life; survival; testosterone

Indexed keywords

BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; GLEASON SCORE; HUMAN; INTERMITTENT ANDROGEN DEPRIVATION THERAPY; METASTASIS; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; BLOOD; DRUG ADMINISTRATION; MALE; PATHOLOGY; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 84908135809     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12626     Document Type: Review

References (51)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer, Update February 2012. Available at: http://www.uroweb.org/gls/pdf/09-Prostate-Cancer-LR.pdf. Accessed February 2013
2. Lepor H, Shore ND,. LHRH agonists for the treatment of prostate cancer: 2012. Rev Urol 2012; 14: 1-12
3. Sharifi N, Gulley JL, Dahut WL,. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010; 17: R305-315
4. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59
5. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-1277
6. Calais da Silva FM Jr, Brausi M, Gonçalves F, et al. Pooled analysis of two protocols of intermittent hormonal therapy, in advanced prostatic cancer. Eur Urol Suppl 2012; 11: abstract e132
7. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF,. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 2013; 31: 549-556
8. Salonen AJ, Taari K, Ala-Opas M, et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012; 187: 2074-2081
9. Salonen AJ, Taari K, Ala-Opas M, et al. Advance prostate cancer treated with intermittent or continous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur Urol 2013; 63: 111-120
10. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-3990
11. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314-1325
12. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895-903 [erratum, NEJM 2012; 367:2262]
13. Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM, the TAP22 Investigators Group. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int 2012; 110: 1262-1269
14. Tunn UW, Canepa G, Kochanowsky A, Kienle E,. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis 2012; 15: 296-302
15. Calais da Silva F, Calais da Silva FM, Gonçalves F, et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised Phase 3 study by the South European Uroncological Group. Eur Urol 2013; pii: S0302-2838(13)00342-4, DOI: 10.1016/j.eururo.2013.03.055
16. American Urological Association. Prostate Cancer. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. Available at: http://www.auanet.org/education/guidelines/prostate-cancer.cfm. Accessed February 2013
17. Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE,. Androgen deprivation therapy: past, present and future. BJU Int 2012; 109 (Suppl. 6): 1-12
18. Tombal B,. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urol Int 2009; 83: 373-378
19. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW, ADT Survivorship Working Group. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med 2010; 7: 2996-3010
20. Walker LM, Robinson JW,. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer. J Sex Marital Ther 2010; 36: 154-165
21. Grossmann M, Zajac JD,. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 2011; 74: 289-293
22. Studer UE, Whelan P, Wimpissinger F, et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol 2013; pii: S0302-2838(13)00739-2. doi: 10.1016/j.eururo.2013.07.024
23. Klotz L, Toren P,. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Curr Oncol 2012; 19 (Suppl. 3): S13-21
24. Mitin T, Efstathiou JA, Shipley WU,. Urological cancer. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol 2012; 9: 672-673
25. Sciarra A, Abrahamsson PA, Brausi M, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 Trials. Eur Urol 2013; 64: 722-730
26. Niraula S, Le LW, Tannock I,. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013; 31: 2029-2036
27. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1: 163-171
28. Briganti A, Joniau S, Gontero P, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 2012; 61: 584-592
29. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013-1021
30. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585-591
31. Verhagen PC, Schröder FH, Collette L, Bangma CH,. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 2010; 58: 261-269
32. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479
33. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29: 2040-2045
34. Dorff TB, Glode LM,. Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Curr Opin Urol 2013; 23: 366-371
35. Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007; 25 (Suppl.): abstract 5015
36. Verhagen PC, Wissenburg LD, Wildhagen MF, et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. Eur Urol 2008; (Suppl.) 7: abstract 541
37. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G,. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43: 233-239
38. Gleave M, Klotz L, Taneja SS,. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 2009; 27: 81-86
39. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr,. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-2550
40. D'Amico AV, Chen MH, de Castro M, et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol 2012; 13: 189-195
41. Fitzpatrick JM, Banu E, Oudard S,. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 2009; 103: 578-587
42. Keizman D, Huang P, Antonarakis ES, et al. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate 2011; 71: 1608-1615
43. Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005; 173: 1567-1571
44. Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007; 99: 1056-1065
45. Isidori AM, Giannetta E, Pozza C, Bonifacio V, Isidori A,. Androgens, cardiovascular disease and osteoporosis. J Endocrinol Invest 2005; 28 (Suppl.): 73-79
46. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027-2038
47. Irani J, Celhay O, Hubert J, et al. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008; 54: 382-391
48. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-1295
49. Perachino M, Cavalli V, Bravi F,. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105: 648-651
50. Fui MN, Grossmann M,. Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more. Asian J Androl 2013; 15: 445-446
51. Malone S, Perry G, Eapen L, et al. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Int J Radiat Oncol Biol Phys 2007; 68: 699-706